Teva opts out of Rexahn partnership
This article was originally published in Scrip
Teva Pharmaceutical Industries decided not to exercise its option to develop the DNA and RNA synthesis inhibitor RX-3117 from Rexahn Pharmaceuticals for the treatment of solid tumors just before the small molecule drug was set to enter human clinical trials in the US.
You may also be interested in...
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.